Triple PET imaging could sharpen epilepsy surgery targeting

NCT ID NCT07147309

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether combining three different PET scans can more accurately pinpoint the brain area causing seizures in people with drug-resistant epilepsy. The three tracers measure glucose metabolism, synaptic density, and inflammation, each highlighting different features of epileptic tissue. Participants will undergo all three scans before surgery, and researchers will compare the imaging results with surgical outcomes to see which combination best guides removal of the seizure focus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
three PET tracers: 18F-FDG, SV2A, and TSPO
What this could lead to
If successful, this approach could improve surgical outcomes for drug-resistant epilepsy by more precisely identifying the brain tissue that needs to be removed.
What could go wrong
This is a small, early-stage imaging study, not a treatment trial. The tracers may not improve surgical planning enough to change outcomes, and the results may not apply to all epilepsy types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Fujian Medical University

    RECRUITING

    Fuzhou, Fujian, 350005, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.